Lupin Announces Launch of Generic LevaquinÃ‚® Tablets
BALTIMORE, June 22, 2011 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil's Levaquin® (levofloxacin) tablets. Commercial shipment of the product has commenced.
Lupin's levofloxacin 250 mg, 500 mg and 750 mg tablets are the AB-rated generic equivalent of Levaquin, a synthetic broad spectrum antibacterial agent used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Levaquin tablets had annual sales of approximately $1.6 billion for the twelve months ended March 2011, based on IMS Health sales data.
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant market share in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition holding global leadership positions in the Anti-TB and Cephalosporins space.
Today, Lupin is the 5th largest and fastest growing Top 5 generics player in the US (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)
For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 million and Rs. 8,626 million respectively. Please visit http://www.lupinworld.com  for more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to d